Enterprise League logo
Immunis, Inc. Logo

Immunis, Inc.

Irvine, United States (US) · Health and Medical

Do you work at Immunis, Inc.?

Claim this profile to manage your company.

Verified by Enterprise League

Data quality

Complete · Accuracy

#sarcopenia

#muscle atrophy

#metabolism

#cell therapy

#secretome

#human healthspan

#muscle health

#obesity

Immunis, Inc. is a Health and Medical company based in Irvine, United States (US), founded in 2019, with 10-20 employees. Immunis, Inc.'s profile is verified on Enterprise League.

Overview

Immunis, Inc is a California-based biotechnology company pioneering stem cell-derived secretome biologics to combat age-related immune dysfunction and muscle wasting.

We are dedicated to maximizing health span and minimizing disease through the advancement of transformative medicine. Our innovative approach focuses on IMM01-STEM, a clinically advanced, first-in-class secretome product, targeting the underlying factors of aging that drive muscle and metabolic disease.

Immunis leverages the power of secretomes – the total set of factors secreted by cells – to deliver a multi-active therapeutic that simultaneously decreases fat and enhances muscle, offering a novel solution for conditions like sarcopenia, osteoarthritis, and obesity.

Recent recognition includes being named one of the "Top 50 Healthcare Technology Companies of 2025" by The Healthcare Technology Report.
Visit Official Website

Most teams do this before shortlisting


Contact Details

contact@immunisbiomedical.com

Irvine, United States (US), 18301 Von Karman Ave

Founded

2019

Company Type

Private Limited Company

Employees

10-20

Categories

Biopharma
Life Science
Biotechnology

Keywords

#sarcopenia

#muscle atrophy

#metabolism

#cell therapy

#secretome

#human healthspan

#muscle health

#obesity

Awards

• 2026 OpenSee all

Products

Default Product Image
IMM01-STEM
Biotechnology

An investigational, stem cell-derived secretome product designed to regenerate muscle, enhance muscle function, and improve metabolic health. It’s a complex biologic comprised of regenerative factors that impact multiple signaling pathways.

N/A


Services

Default Product Image
STEM-MYO Program
Biotechnology

A Phase 1/2a clinical trial testing the safety, tolerability, and preliminary efficacy of IMM01-STEM in elderly individuals with age-related muscle atrophy associated with knee osteoarthritis.

N/A

Companies teams usually look at after Immunis, Inc.

Comparing a few options usually leads to better decisions






  • Save companies to compare later. Useful when sharing options with your team

This is how your company profile looks to others.